Bioatla to participate in the jefferies london healthcare conference

San diego, nov. 08, 2022 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that scott smith, president and sheri lydick, senior vice president, commercial strategy will participate in a fireside chat and one-on-one investor meetings at the jefferies london healthcare conference, to be held in london, uk november 15-17, 2022.
BCAB Ratings Summary
BCAB Quant Ranking